Please provide your email address to receive an email when new articles are posted on . A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone ...

Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The diagnosis ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ...

Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data. Rituximab was found to be superior to ...

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Antigen-specific immunosuppression is a goal in the experimental treatment of autoimmune diseases. In a recent study involving a mouse model of pemphigus vulgaris, Ellebrecht, Payne, and colleagues 1 ...

Paraneoplastic pemphigus is typically a side effect of a cancerous tumor and can cause mouth pain and oral sores. It can be aggressive and should be diagnosed and treated as soon as possible.